GPCR

On May 15, 2026, Deep Track Capital disclosed a new position in Alumis (NASDAQ:ALMS), acquiring 6,772,595 shares—an estimated $169.31 million trade based on quarterly average pricing. According to a May 15, 2026 SEC filing, Deep Track Capital reported acquiring 6,772,595 shares of Alumis (NASDAQ:ALMS) during the first quarter of 2026. The estimated transaction value was $169.31 million, based on the period’s average unadjusted closing price. As of March 31, 2026, the fund’s Alumis stake was valued at $149.20 million, reflecting both the purchase and stock price changes during the quarter. Top five holdings after the filing: As of Friday, shares of Alumis were priced at $22.02, up about 355% over the past year and well outperforming the S&P 500, which is up about 28% in the same period. Alumis develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, with lead assets including ESK-001 and A-005. The firm operates a research-driven business model focused on advancing proprietary TYK2 inhibitors through clinical trials toward potential commercialization. It targets healthcare providers and patients affected by autoimmune disorders such as plaque psoriasis, systemic lupus erythematosus, and neurodegenerative diseases. Alumis is a biotechnology company specializing in the development of novel therapies for autoimmune and neuroinflammatory conditions. It leverages expertise in allosteric TYK2 inhibition to advance a pipeline of differentiated clinical candidates. With a focus on unmet medical needs, Alumis aims to establish a competitive edge through innovative science and targeted clinical development strategies. Deep Track has a history of making concentrated healthcare investments, and Alumis fits that playbook as a late-stage biotech with multiple shots on goal and several potentially value-defining catalysts over the next year.The story is increasingly centered on envudeucitinib, the company's TYK2 inhibitor for autoimmune diseases. Recent Phase 3 psoriasis data showed PASI 90 response rates of 68.0% and 62.1% by Week 24, with PASI 100 rates reaching 41.0% and 39.5%. Management says it remains on track to submit an NDA in the fourth quarter of this year, while potentially pivotal Phase 2b lupus data are expected in the third quarter.CEO Martin Babler said the results reinforce the drug's potential to "reshape the...

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the Body Composition and Type 2 Diabetes/Obesity data expected in Q4 2026 Positive end-of-Phase 2 feedback received from FDA; aleniglipron Phase 3 initiation on track for Q3 2026 Initial data from Phase 1 single ascending dose (SAD) study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in Q3 2026; Phase 1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026 Aleniglipron, amylin and combination data to be presented at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026 Cash, cash equivalents and short-term investments of $1.5 billion as of March 31, 2026, expected to provide cash runway through the end of 2028 SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “With positive end of Phase 2 feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight management in the third quarter,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We are also looking forward to our aleniglipron presentation along with presentations on our oral amylin and GLP-1 combination program at the upcoming ADA meeting. With our Phase 1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment, and fixed dose oral combinations for specific patient populations and expanded indications.” Recent and Upcoming Milestones Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight In March 2026, the Comp...

Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Although both drugs have been on the market for just over three years, they have become LLY’s key top-line drivers. In 2025, the drugs generated combined sales of $36.5 billion, comprising around 56% of Eli Lilly’s total revenues. Investors will be closely watching the sales performance of Mounjaro and Zepbound when LLY reports its first-quarter 2026 results on April 30. The robust performance of Mounjaro and Zepbound in the recent quarters has largely been driven by improved domestic supply following the expansion of manufacturing capacity. Additionally, sales of both drugs have been boosted by their rollout across new international markets. The robust momentum of its GLP-1 franchise is a key driver underpinning Eli Lilly’s upbeat 2026 revenue outlook of $80-$83 billion. We believe that stronger penetration in the U.S. market and rising adoption in international markets likely fueled growth in both drugs in the first quarter of 2026. However, some headwinds are expected from lower pricing. Beyond cardiometabolic health, Lilly’s broader portfolio, including the oncology drug Verzenio and immunology drug Taltz, also continues to deliver steady growth. The company’s newly launched drugs, including Omvoh and Ebglyss in immunology, Jaypirca in oncology, and Kisunla in neuroscience, are all contributing to top-line growth. Eli Lilly and Novo Nordisk NVO presently dominate the obesity market. Mounjaro and Zepbound directly compete with NVO’s semaglutide medicines, Ozempic for T2D and Wegovy for obesity. Like Eli Lilly, Novo Nordisk also generates a substantial portion of revenues from both drugs. Novo Nordisk secured the long-awaited FDA approval for its oral Wegovy pill to treat obesity and reduce cardiovascular risk in late December, followed by its commercial launch in early January. This marked a major milestone, making Wegovy the first GLP-1 RA available in an oral form for weight management. Compared with injectable formulations, the pill offers a far more convenient administration option. Earlier this month, Eli Lilly also secured FDA approval for its GLP-1 obesity pill, Foundayo (orforglipron), and was subsequently launched in the United States, making it a di...

Eli Lilly and Company (NYSE:LLY) is included in our list of the 14 hedge fund favorites with strong setup in 2026. On March 30, 2026, Guggenheim updated its model ahead of the first-quarter data and lowered the firm’s price target for Eli Lilly and Company (NYSE:LLY) from $1,168 to $1,163, while keeping a “Buy” rating. The update came in anticipation of the company’s Q1 2026 results. This update coincides with ongoing analyst attention toward Eli Lilly and Company (NYSE:LLY)’s positioning in the rapidly expanding oral obesity market. RBC Capital reaffirmed its “Outperform” rating and $1,250 price target for the stock on March 16, 2026. The firm highlighted that the updated 44-week Phase 2 ACCESS II data for Structure Therapeutics’ aleniglipron appear similar to Eli Lilly and Company (NYSE:LLY)’s Phase 2 data for orforglipron, with no visibly superior profile. According to the investment firm, the data contribute to the competitive debate about oral obesity therapies and may indicate the emergence of a new competitor for market share. However, Eli Lilly and Company (NYSE:LLY)’s own catalyst remains the firm’s primary focus, with orforglipron’s April 10, 2026, PDUFA date and potential launch expected to be the more significant driver of the stock. Eli Lilly and Company (NYSE:LLY) is a healthcare company that specializes in human pharmaceutical products and offers cardiometabolic health & oncology products. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. Disclosure: None. Follow Insider Monkey on Google News.

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026 Cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, expected to provide cash runway through the end of 2028 SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The obesity market is clearly embracing the introduction of new oral treatment options and Structure Therapeutics is well positioned to capture market share in this important therapeutic area,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “In 2025, we delivered positive Phase 2b 36-week data for aleniglipron and advanced ACCG-2671 our first oral small molecule amylin receptor agonist into the clinic. We completed a $748 million financing providing a strong financial balance sheet to continue advancing aleniglipron which has the potential to be best-in-class. Our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment periods, and fixed dose combinations for specific patient populations and expanded indications. The upcoming 44-week data readout with higher doses in ACCESS II, expected in the first quarter, will provide a more complete profile of aleniglipron as we prepare for Phase 3 this year, with additional data readouts expected throughout 2026.” Recent and Upcoming Milestones Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight As reported in December 2025, data from the aleniglipron clinical program included 36-week data from the core Phase 2b ACCESS study and the exploratory...

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025; second oral amylin receptor agonist (ACCG-3535) development candidate declared Strong financial position with cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025 SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We are on schedule to report topline data by year-end 2025 from both the ACCESS and ACCESS II studies of aleniglipron, our once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “In parallel, we plan to initiate a Phase 1 study of ACCG-2671, which we believe to be the most advanced oral small molecule amylin receptor agonist in development, and we have declared a second amylin development candidate to further enhance our leadership position with oral small molecules engaging this attractive target. We believe the future of obesity treatment lies in multiple options and includes oral, combinable, and broadly accessible therapies—principles that define and differentiate our pipeline and development strategy. These upcoming milestones mark meaningful progress toward realizing that vision.” Recent and Upcoming Milestones Aleniglipron (GSBR-1290) - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight ACCESS and ACCESS II Studies on track for topline 36-week data readouts by year-end 2025 ACCESS is a Phase 2b randomized placebo-controlled, 36-week study that enrolled approximately 220 adults with obesity, or overweight with at least one weight-related comorbidity, evaluating doses up to 120 mg of aleniglipron with a four-week titration schedule. An Open Label Extension of the ACCESS study is ongoing. ACCESS II is a Phase 2 randomized placebo-controlled study that enrolled approximately 80 adults with ob...

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at least 2027 SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The ACCESS and ACCESS II studies for aleniglipron, our once-daily oral small molecule GLP-1 program, remain on track for topline data readouts by the end of the year,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “With our continued confidence in aleniglipron’s profile, we have initiated additional supplementary studies to ensure we are well positioned for Phase 3 and to maximize the therapeutic and competitive potential of this program. By the end of 2025, we also plan to initiate the Phase 1 study of ACCG-2671, which we believe represents the most advanced oral small molecule amylin agonist in development. As the obesity field shifts towards combinability of multiple targets and long-term weight loss maintenance, we are excited to lead the way with a highly scalable pipeline of oral small molecule medicines designed to address the substantial unmet needs in obesity management and related metabolic diseases.” Recent and Upcoming Milestones Aleniglipron (GSBR-1290) - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight Ongoing Phase 2b ACCESS and Phase 2 ACCESS II Studies The fully enrolled ACCESS and ACCESS II studies are on track for topline 36-week data readouts by year-end 2025. ACCESS enrolled approximately 220 adults living with obesity, or overweight with at least one weight-related comorbidity, and is designed to evaluate doses up to 120 mg of aleniglipron with a slower four-...

Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Association (ADA) 85th Scientific Sessions in June 2025 Strong financial position with cash, cash equivalents and short-term investments of $836.9 million SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, including obesity, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We are excited by the recent advancements in the oral small molecule GLP-1 field, which will meaningfully expand access and options for patients with obesity and related diseases,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We continue to make strong progress with the Phase 2b ACCESS and ACCESS II studies for aleniglipron, our once-daily oral small molecule GLP-1 program, which are on track for data readout by the end of the year. In addition, we are on track to initiate the Phase 1 study of ACCG-2671, which we believe is the most advanced oral small molecule amylin program in development, by the end of 2025. We’re advancing our powerful foundation for the future of fixed-dose combination therapies which is best addressed with oral small molecules and to make these medicines more broadly accessible and convenient to patients.” Recent and Upcoming Milestones Aleniglipron (GSBR-1290) – Oral Small Molecule Selective GLP-1 Receptor Agonist for the Treatment of Obesity or Overweight with Co-Morbidities The Phase 2b ACCESS and ACCESS II studies are fully enrolled and on track for topline 36-week data by year-end 2025. ACCESS enrolled approximately 220 adults living with obesity, or overweight with a weight-related comorbidity, and is designed to evaluate doses up to 120 mg of aleniglipron with a 4-week titration regimen. ACCESS II enrolled approximately 80 adults living with obesity, or overweight with a weight-related comorbidity, and is designed to evaluate higher doses of aleniglipron (180 mg and 240 mg) with 4-week titration increments. The Phase 2b ACCESS and ACCE...

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. PRIMARY ENDPOINT MET: Eli Lilly announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to launch orforglipron worldwide without supply constraints. This would further Lilly’s mission to reduce chronic diseases like type 2 diabetes, which is expected to impact an estimated 760 million adults by 2050. In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8%, using the efficacy estimand. In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, which is below the American Diabetes Association’s defined threshold for diabetes. In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs at the highest dose. Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not yet attained. The overall safety profile of orforglipron in ACHIEVE-1 was consistent with the established GLP-1 class. Overall treatment discontinuation rat...